Literature DB >> 7955635

Growth retardation and osteoporosis in juvenile chronic arthritis.

P M Woo1.   

Abstract

Disturbance of growth and bone metabolism is a serious problem in juvenile chronic arthritis. The major factors appear to be chronic disease activity and steroid therapy. Retardation of linear growth is due to disturbance of the neuroendocrine axis, where there is no obvious growth hormone deficiency, but marked reduction of the serum concentration of its mediator, insulin growth factor 1 (IGF-1). Its reduced serum concentration may be multifactorial. In addition, there is also evidence of target insensitivity to IGF-1. The role of the inflammatory cytokines in these endocrine disturbances is likely to be very important, and is the subject of current research.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955635

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  5 in total

1.  Musculoskeletal and functional muscle-bone analysis in children with rheumatic disease using peripheral quantitative computed tomography.

Authors:  S Bechtold; P Ripperger; R Dalla Pozza; H Schmidt; R Häfner; H P Schwarz
Journal:  Osteoporos Int       Date:  2004-10-12       Impact factor: 4.507

2.  Growth hormone treatment in children with rheumatic disease, corticosteroid induced growth retardation, and osteopenia.

Authors:  F K Grote; L W A Van Suijlekom-Smit; D Mul; W C J Hop; R Ten Cate; W Oostdijk; W Van Luijk; C J A Jansen-van Wijngaarden; S M P F De Muinck Keizer-Schrama
Journal:  Arch Dis Child       Date:  2005-10-13       Impact factor: 3.791

3.  Growth and bone mineralization in patients with juvenile idiopathic arthritis.

Authors:  Ozgur Okumus; Muferet Erguven; Murat Deveci; Oznur Yilmaz; Mine Okumus
Journal:  Indian J Pediatr       Date:  2008-03       Impact factor: 1.967

Review 4.  Neural immune pathways and their connection to inflammatory diseases.

Authors:  Farideh Eskandari; Jeanette I Webster; Esther M Sternberg
Journal:  Arthritis Res Ther       Date:  2003-09-23       Impact factor: 5.156

5.  Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis.

Authors:  Majed Khraishi; Brad Millson; John Woolcott; Heather Jones; Lisa Marshall; Nicolino Ruperto
Journal:  Pediatr Rheumatol Online J       Date:  2019-09-10       Impact factor: 3.054

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.